Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
Changing attitudes to vaccination after the COVID-19 pandemic could increase adult vaccination rates, improving health outcomes over the longer term
Survey shows that people 50 years of age and older value good health and improved quality of life
Read more -
ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021
ViiV Healthcare announce the presentation of 13 abstracts from its portfolio of pipeline prevention options.
Read more -
GSK announces major renewable energy investment and low carbon inhaler programme alongside Life Sciences sector Race to Zero ‘breakthrough’ at NYC Climate Week
Company announces £50m investment in renewable energy and carbon reduction at major UK and US manufacturing sites
Read more -
GSK receives CHMP positive opinions recommending approval of Nucala (mepolizumab) in three additional eosinophil-driven diseases
Eosinophil-driven diseases are inflammatory conditions associated with elevated levels of eosinophils, a type of white blood cell.
Read more -
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO
The data reflects our commitment to strengthening our oncology pipeline across immuno-oncology, synthetic lethality & oncology cell therapy
Read more -
GSK Consumer Healthcare leads oral care industry with launch of its first carbon neutral toothbrush
73% of consumers say they would definitely change their consumption habits to reduce their environmental impact.
Read more -
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data
Read more -
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours
GARNET study demonstrated objective response rate of 41.6% across dMMR solid tumours
Read more -
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone
Read more -
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
Fourth indication for mepolizumab in the US for eosinophil-driven diseases.
Read more -
GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15% CER Total EPS 27.9p -39% AER, -28% CER; Adjusted EPS 28.1p +46% AER +71% CER
Sales growth driven by strong commercial execution and favourable prior year comparison
Read more -
GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
GlaxoSmithKline plc and Vir Biotechnology, Inc. announce the supply of 220,000 doses of sotrovimab for adults and adolescents with COVID-19.
Read more -
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Immunocompromised individuals are at greater risk of shingles and associated complications than immunocompetent individuals
Read more -
Brian McNamara appointed CEO Designate of new independent Consumer Healthcare company
Brian McNamara, the CEO of GSK Consumer Healthcare, has been appointed as CEO Designate of the new Consumer Healthcare company.
Read more -
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021
Read more -
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare today presented positive findings from the CUSTOMIZE trial
Read more -
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021
Data to be presented underscore the commitment to developing innovative treatment and prevention options
Read more -
GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease
Full results to be presented at a medical meeting later this year
Read more -
GSK unveils plan for one of Europe’s largest life science campuses in Stevenage
Plan aims to unlock up to £400 million of new private investment and create up to 5,000 new highly-skilled jobs over next decade.
Read more -
New study shows more needs to be done to raise public awareness on the impact of good oral health habits on overall health
A new study by Ipsos and GSK Consumer Healthcare reveals the need to improve public awareness of the benefits of good oral health.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
